
Enanta Pharmaceuticals, Inc.: updates and filings
Price
$7.98
November 19, 2026Market cap $230M
What Ploutos Investor adds for Enanta Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 15 fiscal years, from FY2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 16, 2026next Feb 10, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Annual reportfor the period to Sep 30, 2026Form10-K
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 16, 2026Results of operationsForm8-K
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 29, 2026Other material eventsForm8-K
- Oct 28, 2026Officer or director change, Regulation FD disclosureForm8-K
- Oct 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 10, 2026Results of operationsForm8-K
- Jul 2, 2026Material agreement enteredForm8-K
- Jun 23, 2026Other material eventsForm8-K
- Jun 18, 2026Regulation FD disclosureForm8-K
- May 13, 2026Shares registered for employeesFormS-8
- May 13, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 11, 2026Results of operationsForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 26, 2026Other material eventsForm8-K
- Mar 12, 2026Officer or director change, shareholder voteForm8-K
- Feb 20, 2026FilingFormEFFECT
- Feb 17, 2026Correspondence with the SECFormCORRESP
- Feb 17, 2026Letter from the SECFormUPLOAD
- Feb 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 11, 2026Shelf registration for future offeringsFormS-3
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | 10-K | Annual reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 29, 2026 | 8-K | Other material events | Document |
| Oct 28, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Oct 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 10, 2026 | 8-K | Results of operations | Document |
| Jul 2, 2026 | 8-K | Material agreement entered | Document |
| Jun 23, 2026 | 8-K | Other material events | Document |
| Jun 18, 2026 | 8-K | Regulation FD disclosure | Document |
| May 13, 2026 | S-8 | Shares registered for employees | Document |
| May 13, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 11, 2026 | 8-K | Results of operations | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 26, 2026 | 8-K | Other material events | Document |
| Mar 12, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| Feb 20, 2026 | EFFECT | Filing | Document |
| Feb 17, 2026 | CORRESP | Correspondence with the SEC | Document |
| Feb 17, 2026 | UPLOAD | Letter from the SEC | Document |
| Feb 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 11, 2026 | S-3 | Shelf registration for future offerings | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 21, 2002.
The full analysis
What do Enanta Pharmaceuticals's filings show?
The filings are where every one of Enanta Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.